All In Biotech

Free tool

FAERS Monitor: Intuniv

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022037 or its brand name (Intuniv, Guanfacine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

7,123

Serious

4,202

59% of reports

Hospitalization

1,691

Death reported

218

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective740
  • off label use588
  • somnolence433
  • aggression362
  • fatigue311
  • hypotension277
  • dizziness264
  • headache255
  • intentional overdose252
  • suicidal ideation252
  • insomnia250
  • anxiety248
  • bradycardia248
  • nausea235
  • toxicity to various agents217

Reports by year received

View as table
YearReports
20051
20064
20073
20081
200910
2010101
2011202
2012178
2013201
2014315
2015486
2016457
2017467
2018468
2019476
2020473
2021485
2022537
2023586
2024604
2025536
2026532

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,036 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
aggressionSignal36221.519.47,023
bradycardiaSignal24813.912.32,943
intentional overdoseSignal25211.610.32,439
suicidal ideationSignal2528.17.21,576
somnolenceSignal4336.45.81,966
hypotensionSignal2774.13.6647
toxicity to various agentsSignal2173.83.3449
insomniaSignal2502.82.5285
anxietySignal2482.62.3240
off label use5882.01.8298
drug ineffective7401.71.5206
dizziness2641.61.454
headache2551.21.19
fatigue3111.21.19
nausea2350.90.84

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.